Evaluation of an antibody-free ADP detection assay: ADP-Glo.

Identification of kinase, especially protein kinase, modulators through high-throughput screening (HTS) has become a common strategy for drug discovery programs in both academia and the pharmaceutical industry. There are a number of platform technologies that can be used for measuring kinase activities. However, there is none that fits all criteria in terms of sensitivity, ATP tolerance, robustness, throughput, and cost-effectiveness. Therefore, development of a homogeneous and robust HTS assay for some kinase targets is still challenging. We recently evaluated the ADP-Glo assay from Promega. This is a homogeneous, signal increase assay that measures ADP production from a kinase reaction by coupled enzymes that first convert ADP to ATP and subsequently quantifies ATP using luciferase in the presence of luciferin. Since the unused ATP in the reaction is depleted prior to ADP to ATP conversion, this assay shows excellent sensitivity over a wide range of ATP concentrations. We demonstrate that ADP-Glo assay can be used for 2 kinase targets that belong to different classes, and compare the results of compound profiling with SPA and FP assay technologies.

[1]  Michael Kracht,et al.  Targeting innate immunity protein kinase signalling in inflammation , 2009, Nature Reviews Drug Discovery.

[2]  P. Broad,et al.  Identification of kinase inhibitors by an ATP depletion method. , 2004, Assay and drug development technologies.

[3]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[4]  M. Warmuth,et al.  Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies , 2008, Expert opinion on drug discovery.

[5]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[6]  R. Talanian,et al.  Current in vitro kinase assay technologies: the quest for a universal format. , 2008, Current drug discovery technologies.

[7]  R. Lowery,et al.  Transcreener™: screening enzymes involved in covalent regulation , 2006, Expert opinion on therapeutic targets.

[8]  Ricardo Macarrón,et al.  Design and Implementation of High Throughput Screening Assays , 2011, Molecular biotechnology.

[9]  T. Okabe,et al.  High-throughput screening with quantitation of ATP consumption: a universal non-radioisotope, homogeneous assay for protein kinase. , 2004, Assay and drug development technologies.

[10]  S. Deacon,et al.  The challenge of selecting protein kinase assays for lead discovery optimization , 2008, Expert opinion on drug discovery.

[11]  R. Eglen,et al.  A Generic, Homogenous Method for Measuring Kinase and Inhibitor Activity via Adenosine 5′-Diphosphate Accumulation , 2006, Journal of biomolecular screening.

[12]  Robert A. Copeland,et al.  Defining Balanced Conditions for Inhibitor Screening Assays That Target Bisubstrate Enzymes , 2009, Journal of biomolecular screening.

[13]  C. Quinn,et al.  Evaluating the utility of the HTRF Transcreener ADP assay technology: a comparison with the standard HTRF assay technology. , 2009, Analytical biochemistry.

[14]  R. Eglen,et al.  The current status of drug discovery against the human kinome. , 2009, Assay and drug development technologies.

[15]  Ken Garber,et al.  The second wave in kinase cancer drugs , 2006, Nature Biotechnology.

[16]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[17]  Christopher P Austin,et al.  High-throughput screening assays for the identification of chemical probes. , 2007, Nature chemical biology.

[18]  P. Cohen Targeting protein kinases for the development of anti-inflammatory drugs. , 2009, Current opinion in cell biology.

[19]  A. Joly,et al.  Identification of small molecule ceramide kinase inhibitors using a homogeneous chemiluminescence high throughput assay. , 2007, Assay and drug development technologies.